LA JOLLA, Calif., Dec. 17, 2025 — Singlera Genomics announced a strategic research collaboration with the University of Pittsburgh (Pitt) to advance the preclinical evaluation of an early pancreatic cancer blood test, marking a significant step toward improving detection of one of the deadliest malignancies. The partnership will focus on evaluating BT-Reveal™ Early Pancreatic Cancer Test, a laboratory-developed assay that leverages DNA methylation signatures in circulating cell-free DNA to identify cancer signals before symptoms emerge, positioning the program for future FDA-guided longitudinal studies.
Science Significance
From a scientific standpoint, the collaboration underscores the growing importance of epigenetic biomarkers in early cancer detection. Pancreatic cancer is notoriously difficult to diagnose at an early stage due to its deep anatomical location and lack of early symptoms. Singlera’s proprietary mTitan platform applies advanced DNA methylation analysis to circulating cell-free DNA, enabling detection of cancer-associated methylation haplotypes across multiple tumor types. The Pitt study will assess the sensitivity, specificity, and biological relevance of these methylation signals in high-risk populations, helping to establish whether non-invasive liquid biopsy screening can reliably identify pancreatic cancer at a stage when intervention is still possible. This work contributes to a broader shift toward molecularly informed, minimally invasive diagnostics in oncology.
Regulatory Significance
The regulatory implications are substantial. BT-Reveal™ has already received FDA Breakthrough Device Designation, signaling that regulators recognize its potential to address a serious unmet medical need. The collaboration with Pitt represents a critical preclinical evidence-generation phase, designed to inform the structure of a future large-scale FDA longitudinal study. From a cGxP perspective, the test is currently offered through a CAP- and CLIA-certified clinical laboratory, ensuring adherence to stringent quality, validation, and operational standards. Data generated through this collaboration will be essential for regulatory engagement, clinical performance validation, and risk-benefit assessment as the program progresses toward broader clinical adoption.
Business Significance
Advertisement
For Singlera Genomics, the collaboration strengthens its strategic positioning in the early cancer detection market, a rapidly expanding segment of precision medicine. Partnering with a leading academic medical center such as Pitt enhances scientific credibility, data robustness, and translational potential. The effort also supports Singlera’s broader commercial strategy of advancing its mTitan methylation platform across multiple oncology indications. Demonstrating clinical utility in pancreatic cancer — a disease with high mortality and limited screening options — could significantly expand the commercial and partnership value of the technology, attracting interest from healthcare systems, diagnostics partners, and biopharma organizations focused on early intervention.
Patients’ Significance
For patients, particularly those at high risk for pancreatic cancer, the potential impact is profound. Pancreatic cancer is often diagnosed at an advanced stage, leaving limited therapeutic options and poor survival outcomes. A simple blood-based screening test capable of identifying cancer earlier could enable timelier imaging, intervention, and treatment, fundamentally changing the patient journey. By focusing on non-invasive detection, the Singlera-Pitt collaboration aligns with patient-centric care models that aim to reduce diagnostic burden while increasing the likelihood of meaningful clinical benefit. Earlier detection also opens the door to less aggressive treatment strategies and improved quality of life.
Policy Significance
At the policy level, the initiative reflects broader healthcare priorities centered on early detection, prevention, and cost-effective cancer care. Policymakers and regulators increasingly recognize that late-stage cancer treatment drives disproportionate healthcare costs and poor outcomes. Technologies that enable earlier diagnosis in high-risk populations align with public health goals of reducing mortality and long-term treatment burden. The FDA’s Breakthrough Device framework, under which BT-Reveal™ has been designated, exemplifies policy efforts to accelerate patient access to transformative diagnostic innovations while maintaining rigorous evidence standards.
The collaboration between Singlera Genomics and the University of Pittsburgh highlights how advanced genomic science, regulatory foresight, and clinical research excellence can converge to address one of oncology’s most pressing challenges. By advancing preclinical evaluation of a DNA methylation-based early detection test, the partners are laying the groundwork for future regulatory studies and potential clinical adoption. For the cGxP.wire audience, this development illustrates the critical role of quality-driven clinical research and regulated diagnostics in shaping the future of early cancer detection and improving outcomes for patients facing pancreatic cancer.
Source: Singlera Genomics press release
